
Hikma Pharmaceuticals PLC
LSE:HIK

Intrinsic Value
The intrinsic value of one
HIK
stock under the Base Case scenario is
3 531.71
GBX.
Compared to the current market price of 1 885 GBX,
Hikma Pharmaceuticals PLC
is
Undervalued by 47%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Hikma Pharmaceuticals PLC
Fundamental Analysis


Revenue & Expenses Breakdown
Hikma Pharmaceuticals PLC
Balance Sheet Decomposition
Hikma Pharmaceuticals PLC
Current Assets | 2.3B |
Cash & Short-Term Investments | 213m |
Receivables | 973m |
Other Current Assets | 1.1B |
Non-Current Assets | 2.9B |
Long-Term Investments | 62m |
PP&E | 1.3B |
Intangibles | 1.2B |
Other Non-Current Assets | 326m |
Free Cash Flow Analysis
Hikma Pharmaceuticals PLC
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Hikma Pharmaceuticals PLC
Revenue
|
3.2B
USD
|
Cost of Revenue
|
-1.7B
USD
|
Gross Profit
|
1.4B
USD
|
Operating Expenses
|
-819m
USD
|
Operating Income
|
629m
USD
|
Other Expenses
|
-270m
USD
|
Net Income
|
359m
USD
|
HIK Profitability Score
Profitability Due Diligence
Hikma Pharmaceuticals PLC's profitability score is 58/100. The higher the profitability score, the more profitable the company is.

Score
Hikma Pharmaceuticals PLC's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
HIK Solvency Score
Solvency Due Diligence
Hikma Pharmaceuticals PLC's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Score
Hikma Pharmaceuticals PLC's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
HIK Price Targets Summary
Hikma Pharmaceuticals PLC
According to Wall Street analysts, the average 1-year price target for
HIK
is 2 469.93 GBX
with a low forecast of 2 020 GBX and a high forecast of 3 255 GBX.
Dividends
Current shareholder yield for HIK is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
HIK
stock under the Base Case scenario is
3 531.71
GBX.
Compared to the current market price of 1 885 GBX,
Hikma Pharmaceuticals PLC
is
Undervalued by 47%.